Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab
Boris Gorovits, Daniel Baltrukonis, Indranil Bhattacharya, et al.
Clinical & Experimental Immunology (2018) Vol. 192, Iss. 3, pp. 348-365
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
HoUng Kim, Rieke Alten, Luisa Avedano, et al.
Drugs (2020) Vol. 80, Iss. 2, pp. 99-113
Open Access | Times Cited: 76
Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19
Erik H Vogelzang, Floris C. Loeff, Ninotska I. L. Derksen, et al.
The Journal of Immunology (2020) Vol. 205, Iss. 12, pp. 3491-3499
Open Access | Times Cited: 75
Immunogenicity of biologic agents in rheumatology
Vibeke Strand, João Gonçalves, John D. Isaacs
Nature Reviews Rheumatology (2020) Vol. 17, Iss. 2, pp. 81-97
Closed Access | Times Cited: 68
AURIEL ‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
Jana Hercogová, Kim Papp, V. Chyrok, et al.
British Journal of Dermatology (2019) Vol. 182, Iss. 2, pp. 316-326
Open Access | Times Cited: 58
Assessment of cell cycle regulators in human peripheral blood cells as markers of cellular senescence
Lihuan Guan, Karen Crasta, Andrea B. Maier
Ageing Research Reviews (2022) Vol. 78, pp. 101634-101634
Open Access | Times Cited: 32
Switching Among Biosimilars: A Review of Clinical Evidence
Eleonora Allocati, Brian Godman, Marco Gobbi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 30
Therapeutic drug monitoring and neutralizing anti-drug antibody detection to optimize TNF-alpha inhibitor treatment for uveitis
H Chen, Jenny Shunyakova, Amit K. Reddy, et al.
Frontiers in Ophthalmology (2025) Vol. 5
Open Access
The first WHO reference panel for Infliximab anti-drug antibodies: a step towards harmonizing therapeutic drug monitoring
Meenu Wadhwa, Isabelle Cludts, Eleanor Atkinson, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
Vibeke Strand, João Gonçalves, Timothy P. Hickling, et al.
BioDrugs (2019) Vol. 34, Iss. 1, pp. 27-37
Open Access | Times Cited: 45
Immunogenicity of biologic therapies for migraine: a review of current evidence
Joshua M. Cohen, Xiaoping Ning, Yoel Kessler, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 36
Reduced Graphene Oxide Electrolyte‐Gated Transistor Immunosensor with Highly Selective Multiparametric Detection of Anti‐Drug Antibodies
Matteo Sensi, Rafael Furlan de Oliveira, Marcello Berto, et al.
Advanced Materials (2023) Vol. 35, Iss. 36
Open Access | Times Cited: 12
Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents
Xian Pan, Felix Stader, Khaled Abduljalil, et al.
The AAPS Journal (2020) Vol. 22, Iss. 4
Closed Access | Times Cited: 33
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Tessa Straatmijer, Vince Biemans, Dirk Jan A. R. Moes, et al.
Digestive Diseases and Sciences (2023) Vol. 68, Iss. 6, pp. 2647-2657
Open Access | Times Cited: 11
Anti-drug antibody detection with label-free electrolyte-gated organic field-effect transistors
Matteo Sensi, Marcello Berto, Sara Gentile, et al.
Chemical Communications (2020) Vol. 57, Iss. 3, pp. 367-370
Open Access | Times Cited: 30
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
HoUng Kim, Rieke Alten, Fraser Cummings, et al.
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 23
Update on the systemic management of noninfectious uveitis in children and adolescents
Inês Leal, Laura R Steeples, Shiao Wei Wong, et al.
Survey of Ophthalmology (2023) Vol. 69, Iss. 1, pp. 103-121
Open Access | Times Cited: 9
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
Christopher J Edwards, Joëlle Monnet, Martin Ullmann, et al.
Clinical Rheumatology (2019) Vol. 38, Iss. 12, pp. 3381-3390
Open Access | Times Cited: 24
Relative Efficacy and Safety of Anti-Inflammatory Biologic Agents for Osteoarthritis: A Conventional and Network Meta-Analysis
Yang Li, Yiying Mai, Peihua Cao, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 14, pp. 3958-3958
Open Access | Times Cited: 13
Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients
Ilana Reinhold, Sena Blümel, Jens Schreiner, et al.
Inflammatory Intestinal Diseases (2020) Vol. 6, Iss. 1, pp. 38-47
Open Access | Times Cited: 18
An Integrated Analysis of Dostarlimab Immunogenicity
Sharon Lu, Ronald R. Bowsher, Amanda Clancy, et al.
The AAPS Journal (2021) Vol. 23, Iss. 5
Open Access | Times Cited: 16
Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn’s disease
Kouzhu Zhu, Xiaoliang Ding, Zhiyao Chen, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review
Manuel Busto-Iglesias, Lorena Rodríguez-Martínez, Carmen Antía Rodríguez-Fernández, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 766-766
Open Access | Times Cited: 6
Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial
Astrid M. van Huizen, G. E. van der Kraaij, Celine Busard, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 9, pp. 1815-1824
Open Access | Times Cited: 6
Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics
Boris Gorovits, Kun Peng, Arno Kromminga
BioDrugs (2019) Vol. 34, Iss. 1, pp. 39-54
Closed Access | Times Cited: 19
Current Considerations for Immunoglobulin Isotype Characterization of Antibody Response against Biotherapeutics
Boris Gorovits
The AAPS Journal (2020) Vol. 22, Iss. 6
Closed Access | Times Cited: 16
Page 1 - Next Page

Scroll to top